Jubilant Life Sciences’ wholly-owned subsidiary -- Jubilant Pharma (JPL), a company incorporated under the laws of Singapore, has successfully priced its rated unsecured bonds at 6.00% per annum issued at par for $200 million maturing in March, 2024.
S&P Global Ratings (S&P) has affirmed ‘BB-/positive’ rating and Fitch Ratings (Fitch) has affirmed ‘BB-/Stable’ rating for JPL. The Notes have been rated ‘BB-’ by S&P and ‘BB’ by Fitch.
The major portion of the net proceeds of the Notes shall be used to refinance existing indebtedness and pay associated fees and premiums over a period of time and the balance amount for working capital and general corporate purposes.
Jubilant Life Sciences is an integrated global pharmaceutical and life sciences company engaged in Pharmaceuticals, Life Science Ingredients and Drug Discovery Solutions.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: